Ombudsman 'not satisfied' with EMA's explanation of disclosure policy changes
This article was originally published in SRA
Executive Summary
The battle of wits between the European Medicines Agency and the European Ombudsman over the EMA's clinical trial data disclosure policy has ratcheted up a couple of notches. The ombudsman, Emily O'Reilly, has rejected the agency's arguments in defence of changes to the policy, saying it has "clearly stepped back" from allowing independent review of the data.
You may also be interested in...
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.